,address1,city,state,zip,country,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,2805 Place Louis-R Renaud,Laval,QC,H7V 0A3,Canada,https://www.crescitatherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.","{'maxAge': 1, 'name': 'Mr. Serge  Verreault B.A., M.B.A.', 'title': 'Pres, CEO & Director', 'fiscalYear': 2022, 'totalPay': 632250, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.67,0.67,0.67,0.67,0.67,0.67,0.67,0.67,0.0,1.89318,13.400001,15248,15248,20229,9000,9000,0.67,0.7,0,0,13650714,0.495,0.79,0.6254336,0.688,0.6855,0.0,0.0,CAD,4837682,0.037520003,18216123,20374200,3322,5072,1690761600,1693440000,0.0002,0.098950006,0.0,0.18,1.013,0.6614018,1672444800,1703980800,1688083200,819000,0.05,0.222,3.608,TOR,EQUITY,CTX.TO,CTX.TO,CRESCITA THERAPEUTICS INC,Crescita Therapeutics Inc.,1531229400,America/Toronto,EDT,-14400000,0.67,none,10226000,0.502,1341000,1413000,2.916,4.081,21826000,6.862,1.069,0.00559,0.040430002,13182000,-37250,453000,-0.207,0.57858,0.061440002,0.01113,CAD,
1,2805 Place Louis-R Renaud,Laval,QC,H7V 0A3,Canada,https://www.crescitatherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.","{'maxAge': 1, 'name': 'Mr. Jose  DaRocha C.A., CPA', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'totalPay': 385600, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.67,0.67,0.67,0.67,0.67,0.67,0.67,0.67,0.0,1.89318,13.400001,15248,15248,20229,9000,9000,0.67,0.7,0,0,13650714,0.495,0.79,0.6254336,0.688,0.6855,0.0,0.0,CAD,4837682,0.037520003,18216123,20374200,3322,5072,1690761600,1693440000,0.0002,0.098950006,0.0,0.18,1.013,0.6614018,1672444800,1703980800,1688083200,819000,0.05,0.222,3.608,TOR,EQUITY,CTX.TO,CTX.TO,CRESCITA THERAPEUTICS INC,Crescita Therapeutics Inc.,1531229400,America/Toronto,EDT,-14400000,0.67,none,10226000,0.502,1341000,1413000,2.916,4.081,21826000,6.862,1.069,0.00559,0.040430002,13182000,-37250,453000,-0.207,0.57858,0.061440002,0.01113,CAD,
2,2805 Place Louis-R Renaud,Laval,QC,H7V 0A3,Canada,https://www.crescitatherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.","{'maxAge': 1, 'name': 'Mr. Francois  Lafortune', 'title': 'Exec. VP & GM', 'fiscalYear': 2022, 'totalPay': 297216, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.67,0.67,0.67,0.67,0.67,0.67,0.67,0.67,0.0,1.89318,13.400001,15248,15248,20229,9000,9000,0.67,0.7,0,0,13650714,0.495,0.79,0.6254336,0.688,0.6855,0.0,0.0,CAD,4837682,0.037520003,18216123,20374200,3322,5072,1690761600,1693440000,0.0002,0.098950006,0.0,0.18,1.013,0.6614018,1672444800,1703980800,1688083200,819000,0.05,0.222,3.608,TOR,EQUITY,CTX.TO,CTX.TO,CRESCITA THERAPEUTICS INC,Crescita Therapeutics Inc.,1531229400,America/Toronto,EDT,-14400000,0.67,none,10226000,0.502,1341000,1413000,2.916,4.081,21826000,6.862,1.069,0.00559,0.040430002,13182000,-37250,453000,-0.207,0.57858,0.061440002,0.01113,CAD,
